Valneva's Legal Storm Overshadows Pfizer's Lyme Vaccine Commitment

Valneva shares plunge 43% amid a U.S. investigation into Lyme vaccine trial data, while partner Pfizer commits to 2026 filings and analysts see a buying opportunity.

Shares of French vaccine developer Valneva SE are navigating turbulent waters, caught between a burgeoning U.S. legal probe and a key partner's steadfast commitment to a major pipeline asset. The stock, which recently found a tentative floor at €2.70, remains deeply wounded, down over 43% in the past month following controversial Phase 3 trial data for its Lyme disease vaccine candidate.

The core of the volatility stems from the VALOR study results for the vaccine, PF-07307405, developed in partnership with Pfizer. While the data demonstrated an efficacy of approximately 74% in preventing confirmed Lyme disease cases, the trial narrowly missed its primary statistical endpoint. This failure was attributed to a lower-than-expected incidence of the disease during the study period, which weakened the statistical power of the analysis. The discrepancy between the company's initial communication and the actual trial outcome has triggered significant investor backlash and formal scrutiny.

U.S. law firm Pomerantz has launched an investigation into whether Valneva and its executives violated securities laws, potentially misleading investors. This legal overhang now dominates the market narrative, pushing other corporate developments into the background.

Despite the statistical hiccup and legal complications, partner Pfizer is pressing forward. The pharmaceutical giant remains committed to submitting regulatory applications for the Lyme vaccine in the second half of 2026. This resolve is echoed by some analysts. Investment bank Jefferies has reiterated its buy rating on Valneva, viewing the steep sell-off as a clear buying opportunity and maintaining a price target of $15. Institutional investors appear to share this contrarian view; Frazier Life Sciences Management recently established a new position worth approximately $8.24 million.

Financially, Valneva reports a stable position for now, with a cash reserve of nearly €110 million and a reduced cash burn rate of 21%. Operationally, there are several points of progress beyond the Lyme program. In Brazil, where its chikungunya vaccine IXCHIQ is already approved, the company has administered over 12,000 doses as part of a pilot vaccination campaign. Furthermore, Valneva secured future milestone payments by licensing the global rights for its antigen technology for a C. difficile vaccine candidate to Elaris FlexCo.

However, significant commercial hurdles persist. The U.S. market for IXCHIQ remains entirely closed after Valneva voluntarily withdrew its applications in January following reports of serious side effects in older patients. This has led market observers to remove U.S. revenue from their models and anticipate subdued demand even in Europe.

Investors are now looking ahead to key dates for clarity. Valneva is scheduled to present commercial updates on IXCHIQ at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15, 2026. This will be followed by the release of its first-quarter financial results on May 7, 2026. The path forward for the stock likely hinges on the resolution of the Pomerantz investigation and Pfizer's continued progress toward regulatory filings, as the market weighs legal risks against tangible pipeline advancements.